Indications
Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Composition
- Active substance
- cabazitaxel
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Jevtana
- Active substance
- cabazitaxel
- ATC code
- L01CD
- Therapeutic area
- Prostatic Neoplasms
- Marketing authorisation holder
- Sanofi Winthrop Industrie
- Status
- Authorised